|
業務類別
|
-- |
|
業務概覽
|
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe. |
| 公司地址
| Boge Alle 6-8, Horsholm, DNK, DK-2970 |
| 電話號碼
| +45 45747576 |
| 傳真號碼
| +45 45748607 |
| 公司網頁
| https://www.alk.net |
| 員工數量
| 2711 |
| Mr. Peter Halling |
Chief Executive Officer and President |
-- |
20/02/2026 |
| Mr. Claus Steensen Solje |
Chief Financial Officer and Executive Vice President |
-- |
20/02/2026 |
| Ms. Lise Lund Maerkedahl |
Director and Project Director, Global Clinical Development |
-- |
20/02/2026 |
| Ms. Katja Barnkob |
Director and Senior Project Director, Global Clinical Development |
-- |
20/02/2026 |
| Ms. Nanna Rassov Carlson |
Director and Senior Manager, QA Release |
-- |
20/02/2026 |
|
|
| Ms. Lene Skole |
Vice Chairman of the Board |
20/02/2026 |
| Mr. Jesper Hoiland |
Independent Director |
20/02/2026 |
| Dr. Bertil Lindmark, M.D.,PhD |
Independent Director |
20/02/2026 |
| Ms. Lise Lund Maerkedahl |
Director and Project Director, Global Clinical Development |
20/02/2026 |
| Mr. Anders Hedegaard |
Chairman of the Board |
20/02/2026 |
| Mr. Lars Erik Holmqvist |
Director |
20/02/2026 |
| Ms. Katja Barnkob |
Director and Senior Project Director, Global Clinical Development |
20/02/2026 |
| Ms. Gitte Pugholm Aabo |
Independent Director |
20/02/2026 |
| Ms. Nanna Rassov Carlson |
Director and Senior Manager, QA Release |
20/02/2026 |
| Mr. Johan Smedsrud |
Director |
20/02/2026 |
| Mr. Alan Main |
Independent Director |
20/02/2026 |
|
|
|
|
